ResearcherJiangsu UniversityNo recent work listed
Yawen Liu
Matched on ORCID iD 0000-0003-2859-4771; OpenAlex author ID A5100686875. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2019: 2 papers · 2020: 1 paper
Papers 3
- Methyl-CpG-binding protein 2 drives the Furin/TGF-β1/Smad axis to promote epithelial-mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1038/s41389-020-00258-y↗
- Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. Co-author DOI 10.7150/jca.32052↗
- The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Co-author PMID 30949406↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Aihua Gong · 3 shared papers, 2019–2020 · strength 0.28
- Paper Methyl-CpG-binding protein 2 drives the Furin/TGF-β1/Smad axis to promote epithelial-mesenchymal transition in pancreat… DOI 10.1038/s41389-020-00258-y↗
- Paper The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. PMID 30949406↗
- Paper Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. DOI 10.7150/jca.32052↗
- Min Xu · 3 shared papers, 2019–2020 · strength 0.28
- Paper Methyl-CpG-binding protein 2 drives the Furin/TGF-β1/Smad axis to promote epithelial-mesenchymal transition in pancreat… DOI 10.1038/s41389-020-00258-y↗
- Paper The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. PMID 30949406↗
- Paper Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis. DOI 10.7150/jca.32052↗
- Huizhi Wang · 2 shared papers, 2019–2020 · strength 0.19
- Wan‐Xin Peng · 1 shared paper, 2020 · strength 0.10
- Youli Zhang · 1 shared paper, 2019 · strength 0.09
- Meiting Zhang · 1 shared paper, 2019 · strength 0.08
- Xiangyu Kong · 1 shared paper, 2019 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.